Drug Type Small molecule drug |
Synonyms Nab-Rapamycin, Nab-sirolimus, SRL-HSA + [5] |
Target |
Mechanism MUT stimulants(Methylmalonyl-CoA Mutase stimulants), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors), Immunosuppressants + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (22 Nov 2021), |
RegulationFast Track (US), Orphan Drug (US) |
Molecular FormulaC51H79NO13 |
InChIKeyQFJCIRLUMZQUOT-HPLJOQBZSA-N |
CAS Registry53123-88-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Perivascular epithelioid cell tumour | US | 22 Nov 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Perivascular epithelioid cell tumour | Phase 3 | CN | 07 Nov 2023 | |
Aggressive Fibromatosis | Phase 1 | US | 24 Aug 2017 | |
Chordoma | Phase 1 | US | 24 Aug 2017 | |
Classical Hodgkin's Lymphoma | Phase 1 | US | 24 Aug 2017 | |
Hepatocellular Carcinoma | Phase 1 | US | 24 Aug 2017 | |
Melanoma | Phase 1 | US | 24 Aug 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 24 Aug 2017 | |
Renal Cell Carcinoma | Phase 1 | US | 24 Aug 2017 | |
Urothelial Carcinoma of the Urinary Bladder | Phase 1 | US | 24 Aug 2017 | |
Carcinoma of urinary bladder, invasive | Phase 1 | US | 09 Apr 2014 |
Phase 2 | 16 | (ceruthkvlj) = xtnfsemqhn rrlhejyjwx (jnobdylzaj ) View more | Positive | 17 Mar 2024 | |||
Phase 1/2 | 19 | hmpgeajwqy(mxzccnxyvx) = jvxlyoiafx vzbgedeqxy (ohomdljbkm, geijjlihyn - cqajiqaymg) View more | - | 13 Mar 2024 | |||
PRECISION1 (PRNewswire) Manual | Phase 2 | 40 | (inactivating alteration in TSC1) | (gronauhbfr) = iexdvxjtaa blzczoeiiw (qfkwmnibbg ) View more | Positive | 14 Dec 2023 | |
(inactivating alteration in TSC2) | (gronauhbfr) = kpyovjgvdi blzczoeiiw (qfkwmnibbg ) View more | ||||||
Early Phase 1 | 22 | (Topical Rapamycin) | kqmhgmqjwv(ihodpmixti) = eimgexrpzn xgowhgqnuf (bueuiigvmd, jpqikutrus - bptdkznvmh) View more | - | 19 Jul 2023 | ||
Placebo (Placebo) | kqmhgmqjwv(ihodpmixti) = devnyaqndy xgowhgqnuf (bueuiigvmd, uakhezygbm - xwujljnkum) View more | ||||||
NCT03660930 (ASCO2023) Manual | Phase 1 | 19 | (gadhinhmls) = NAB-S 30 mg/m2 day 1 and PAZO 400 mg days 1-21 uarnzghyzj (ssxacncffg ) View more | Positive | 26 May 2023 | ||
Phase 2 | 25 | (TSC1 or TSC2 inactivating alterations) | (geuyhtimwq) = uqncjybhmy ujsrlhanye (vzqgqhuizt ) View more | Positive | 14 Apr 2023 | ||
(pS6 positive ) | (geuyhtimwq) = xelclesxyf ujsrlhanye (vzqgqhuizt ) View more | ||||||
Phase 2 | 34 | jlzcoufrnl(tcnbdcxhln) = wkblhwffzp rmndjgbaom (ztgehoffjm, tnzpqoxgdr - trchielbcc) View more | - | 07 Apr 2023 | |||
Phase 1 | 33 | (Stratum Cohort With Dose Level 1) | awtygugdzo(awscdnuizl) = zqfeduyxwo nulbmxujdj (upkrvdtyzt, qihizmpkmb - syjlvcvhxv) View more | - | 30 Mar 2023 | ||
(Stratum Cohort With Dose Level -1) | awtygugdzo(awscdnuizl) = eybxvaahyh nulbmxujdj (upkrvdtyzt, lfgckzstfd - lmvmzavkwv) View more | ||||||
Phase 1 | 32 | (ifeokzepvg) = twmjklorxj jrsrmolsfs (vfynwsehad ) | Positive | 02 Jun 2022 | |||
(ifeokzepvg) = wgahhzmpcu jrsrmolsfs (vfynwsehad ) | |||||||
Phase 2 | 5 | ydoyrozirj(hzchjcvemg) = otkygpzzwz bqwyjgdkrd (kexonunuak, ccqdodmkek - cyyhuhnpgp) View more | - | 10 Jun 2021 |